v3.26.1
Segment Reporting - Schedule of CODM also Reviews DefenCath Sales Separately From Sales (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Product Sales:        
Total Revenue and Grant Income $ 101,931 $ 39,736 $ 229,358 $ 78,818
Product sales, net        
Product Sales:        
Total Revenue and Grant Income 94,341 39,736 216,257 78,818
DefenCath        
Product Sales:        
Total Revenue and Grant Income 66,119 39,736 163,630 78,818
Melinta Portfolio        
Product Sales:        
Total Revenue and Grant Income 28,222 0 52,627 0
Contract revenue        
Product Sales:        
Total Revenue and Grant Income 4,966 0 8,048 0
Grant income        
Product Sales:        
Total Revenue and Grant Income $ 2,624 $ 0 $ 5,053 $ 0